Carlson RW et al. Goserelin plus anastrozole for the treatment of premenopausal women with hormone receptor positive, recurrent/metastatic breast cancer. San Antonio Breast Cancer Symposium 2004;Abstract 6052.

Chan A et al. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: An international phase II trial. Br J Cancer 2006;95(7):788-93. Abstract

De Maio E et al. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: A single-centre phase 2 trial. BMC Cancer 2007;7:50. Abstract

Geyer CE et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-43. Abstract

Gradishar WJ. Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother 2006;7(8):1041-53. Abstract

Gradishar W et al. A randomized phase 2 trial of qw or q3w ABI-007 (ABX) vs q3W solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium 2006;Abstract 46.

Gradishar W et al. Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: First results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 12.

Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract

Guarneri V et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The MD Anderson Cancer Center experience. J Clin Oncol 2006;24(25):4107-15. Abstract

Howell A. Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr Relat Cancer 2006;13(3):689-706. Abstract

Ibrahim NK et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005;23(25):6019-26. Abstract

Mackey JR et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 3.

Mayer EL et al. Novel approaches to advanced breast cancer: Bevacizumab and lapatinib. J Natl Compr Canc Netw 2007;5(3):314-23. Abstract

Miller KD et al. Angiogenesis inhibition in the treatment of breast cancer: A review of studies presented at the 2006 San Antonio breast cancer symposium. Clin Adv Hematol Oncol 2007;5(3):1-12. Abstract

Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). San Antonio Breast Cancer Symposium 2005;Abstract 3.

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract

Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract

Tripathy D. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: Underlying rationale and results of clinical trials. Oncologist 2007;12(4):375-89. Abstract

Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract